Am J Cancer Res 2025;15(9):4198-4199
www.ajcr.us /ISSN:2156-6976/ajcr0168909

Erratum
MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway: Am J Cancer Res. 2019; 9(4): 765-778

Mukun Zhang[1], Heng Zhang[2], Haiou Hong[1], Zhiyong Zhang[3]

[1]Health Management Center, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, Anhui, China; [2]Department of Histology and Embryology, Xiang Ya School of Medicine, Central South University, Changsha, Hunan, China; [3]Department of Surgery, Robert-Wood-Johnson Medical School University Hospital, Rutgers University, The State University of New Jersey, New Brunswick, NJ, USA

Received September 19, 2025; Accepted September 22, 2025; Epub September 25, 2025; Published September 30, 2025

There are two mistakes of repeating picture in **Figure 4C** of MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway. Therefore, we provide the correct version to displace the wrong figures and reflect changes. This article is part of a series of continuous studies by the same team in the field of oncology (liver cancer), with two other related articles published in *Autophagy* and *Oncotarget*. We sincerely apologize for this oversight and any confusion it may have caused. The corrected **Figure 4** is shown below.

Address correspondence to: Haiou Hong, Health Management Center, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, Anhui, China. E-mail: wx20172607799@gmail.com; Zhiyong Zhang, Department of Surgery, Robert-Wood-Johnson Medical School University Hospital, Rutgers University, The State University of New Jersey, New Brunswick, NJ, USA. ORCID: 0000-0001-8576-1607; E-mail: zhangz2@rwjms.rutgers.edu

https://doi.org/10.62347/XRSE9244



Figure 4. Combination treatment with miR-374b and sorafenib re-sensitizes resistant HCC cells to sorafenib treat ment *in vitro and in vivo*. Hep3B and Hep3B-R (A) and HCCLM3 and HCCLM3-R (B) cells were treated with 4 or 10 nM miR-374b and 20 nM sorafenib either singly or in combination and cell survival was analyzed. Hep3B and Hep3B R (C) and HCCLM3 and HCCLM3-R (D) cells were treated with 4 or 10 nM miR-374b and 20 nM sorafenib either singly or in combination for 24 h and the clonogenic ability of the surviving cells was analyzed. Right panels show quantification of the numbers of colonies formed by cells in the respective treatment groups. (E) 2×10^6 Hep3B-R were injected sub-cutaneously into both flanks of SCID mice, and tumor growth was monitored. And the mice were randomly divided into 4 groups (n = 6/group) and treated with: 1) vehicle, 2) 25 mg/kg sorafenib via oral gavage daily for 5 days/week, 3) miR-374b transfection, and 4) a combination of miR-374b and sorafenib daily for 5 days/ week. Tumors (n = 6/group) were monitored twice a week and were harvested and weighed at the end of 3 weeks. Tumor volumes (E) and weights (F) of tumors treated with the combination of miR-374b and sorafenib were signifi cantly decreased. (G) Total RNAs from the tissues were measured by qRT-PCR for the expression levels of hnRNPA1 and PKM2. n = 3 (except E); *P < 0.05, **P < 0.01, ***P < 0.001. *P* values were calculated with student's *t*-test.